Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MME | P08473 | 1/20 | 0.39 |
| ▸ | TYR | P14679 | 7/20 | 0.39 |
| ▸ | MAPT | P10636 | 3/20 | 0.34 |
| ▸ | GAA | P10253 | 2/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | CA3 | P07451 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.33 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | CAPN1 | P07384 | 1/20 | 0.33 |
| ▸ | CA12 | O43570 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9936558 | 0.89 | MME (0.42) | MMETYRMAPTGAACA3 | |
| SCHEMBL9937168 | 0.88 | MME (0.44) | MMETYRMAPTGAAMEN1 | |
| SCHEMBL9969540 | 0.87 | MME (0.41) | MMETYRMAPTGAACA3 | |
| SCHEMBL9936607 | 0.86 | MME (0.39) | MMETYRCA3ALOX5CA12 | |
| SCHEMBL9937162 | 0.86 | MME (0.43) | MMETYRMAPTGAAMEN1 | |
| SCHEMBL9937977 | 0.85 | MME (0.50) | MMETYRSMN1; SMN2 | |
| SCHEMBL9969539 | 0.85 | MME (0.42) | MMETYRMAPTALDH1A1SMN1; SMN2 | |
| SCHEMBL15341183 | 0.84 | MME (0.49) | MMETYRMAPTGAAALDH1A1 | |
| SCHEMBL15328999 | 0.84 | MME (0.46) | MMETYRMAPTGAAMEN1 | |
| SCHEMBL18675888 | 0.84 | CA12 (0.38) | MMETYRNPC1RAB9ACA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2651886-B1 | METHOD FOR DEPIGMENTING KERATIN MATERIALS USING RESORCINOL DERIVATIVES | ORÉAL L (FR) | 2015-03-04 | — | — | EP | claimed |
| US-8937187-B2 | Method for depigmenting keratin materials using resorcinol derivatives | L'OREAL (FR) | 2015-01-20 | — | — | US | claimed |
| US-20130281507-A1 | METHOD FOR DEPIGMENTING KERATIN MATERIALS USING RESORCINOL DERIVATIVES | L'OREAL (FR) | 2013-10-24 | — | — | US | claimed |
| EP-2651886-A1 | METHOD FOR DEPIGMENTING KERATIN MATERIALS USING RESORCINOL DERIVATIVES | L'Oréal (FR) | 2013-10-23 | — | — | EP | claimed |
| WO-2012079938-A1 | METHOD FOR DEPIGMENTING KERATIN MATERIALS USING RESORCINOL DERIVATIVES | L'OREAL (FR) | 2012-06-21 | — | — | WO | claimed |
| EP-3393603-B1 | TOPICAL DELIVERY SYSTEM FOR ACTIVE INGREDIENTS | OREAL (FR) | 2023-01-18 | — | — | EP | disclosed |
| EP-3393603-B1 | TOPICAL DELIVERY SYSTEM FOR ACTIVE INGREDIENTS | OREAL (FR) | 2023-01-18 | — | — | EP | disclosed |
| US-11260000-B2 | Composition in the form of nano or micro emulsion or with lamellar structure | L'OREAL (FR) | 2022-03-01 | — | — | US | disclosed |
| US-11154473-B2 | Composition comprising resorcinol or derivative thereof | L'OREAL (FR) | 2021-10-26 | — | — | US | disclosed |
| US-11154473-B2 | Composition comprising resorcinol or derivative thereof | L'OREAL (FR) | 2021-10-26 | — | — | US | disclosed |
| EP-3171853-B1 | COMPOSITION IN THE FORM OF NANO OR MICRO EMULSION OR WITH LAMELLAR STRUCTURE | OREAL (FR) | 2020-07-29 | — | — | EP | disclosed |
| EP-3171853-B1 | COMPOSITION IN THE FORM OF NANO OR MICRO EMULSION OR WITH LAMELLAR STRUCTURE | OREAL (FR) | 2020-07-29 | — | — | EP | disclosed |
| US-8937187-B2 | Method for depigmenting keratin materials using resorcinol derivatives | L'OREAL (FR) | 2015-01-20 | — | — | US | disclosed |
| US-8937187-B2 | Method for depigmenting keratin materials using resorcinol derivatives | L'OREAL (FR) | 2015-01-20 | — | — | US | disclosed |
| US-20130281507-A1 | METHOD FOR DEPIGMENTING KERATIN MATERIALS USING RESORCINOL DERIVATIVES | L'OREAL (FR) | 2013-10-24 | — | — | US | disclosed |
| US-20130281507-A1 | METHOD FOR DEPIGMENTING KERATIN MATERIALS USING RESORCINOL DERIVATIVES | L'OREAL (FR) | 2013-10-24 | — | — | US | disclosed |
| US-20130281507-A1 | METHOD FOR DEPIGMENTING KERATIN MATERIALS USING RESORCINOL DERIVATIVES | L'OREAL (FR) | 2013-10-24 | — | — | US | disclosed |
| EP-2651886-A1 | METHOD FOR DEPIGMENTING KERATIN MATERIALS USING RESORCINOL DERIVATIVES | L'Oréal (FR) | 2013-10-23 | — | — | EP | disclosed |
| WO-2012079938-A1 | METHOD FOR DEPIGMENTING KERATIN MATERIALS USING RESORCINOL DERIVATIVES | L'OREAL (FR) | 2012-06-21 | — | — | WO | disclosed |
| WO-2012079938-A1 | METHOD FOR DEPIGMENTING KERATIN MATERIALS USING RESORCINOL DERIVATIVES | L'OREAL (FR) | 2012-06-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11154473-B2 | Composition comprising resorcinol or derivative thereof | NQO1, LRAT, RBP4 | MME 2664/4885TYR 4/4885MAPT 1980/4885 |
| US-20130281507-A1 | METHOD FOR DEPIGMENTING KERATIN MATERIALS USING RESORCINOL DERIVATIVES | KRT18, KLHL20, IK | MME 2679/4885TYR 9/4885MAPT 68/4885 |
| US-11260000-B2 | Composition in the form of nano or micro emulsion or with lamellar structure | LRAT, LIPA, DAGLA | MME 2932/4885TYR 194/4885MAPT 1261/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.